Retatrutide 40mg

Retatrutide 40mg Overview

Retatrutide is a synthetic peptide investigated for activity across three receptor systems involved in metabolic signalling: the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors.

This combined receptor profile has led to Retatrutide being described within scientific literature as a triple receptor agonist, distinguishing it from compounds investigated through only one or two of these pathways.

Published research involving Retatrutide includes receptor pharmacology, preclinical experimental models and human clinical trials examining combined GIP, GLP-1 and glucagon receptor activity.

This 40mg presentation provides the highest-quantity Retatrutide option currently available within our range for laboratory research requiring larger quantities of research material.

Interlink Peptides supplies Retatrutide 40mg strictly for laboratory and scientific research applications.

Technical Specification

Compound: Retatrutide
Quantity: 1 × 40mg vial
Form: Lyophilised powder
Peptide type: Synthetic GIP / GLP-1 / glucagon receptor triple agonist
CAS Number: 2381089-83-2
Molecular weight: Approximately 4,731 Da
Storage: −20 °C in lyophilised form
After reconstitution: Store refrigerated at 2–8 °C
Certificate of Analysis: Available for this product

Exact analytical specifications should be confirmed using the Certificate of Analysis applicable to the relevant batch.

Research Background

Retatrutide has generated substantial scientific interest because it combines activity involving three metabolically relevant receptor systems within a single molecule.

GIP and GLP-1 are extensively investigated within incretin and metabolic research. Retatrutide additionally incorporates glucagon-receptor activity, enabling researchers to investigate simultaneous signalling involving all three receptor systems.

Published research includes molecular and receptor studies, animal models and human clinical trials. Areas investigated include glucose and lipid metabolism, energy regulation and wider metabolic signalling.

Retatrutide’s triple-receptor profile also distinguishes it from Tirzepatide, which is investigated primarily through dual GIP and GLP-1 receptor activity.

The existence of human clinical research does not make the research material supplied by Interlink Peptides a medicinal product. We make no claims regarding weight loss, appetite reduction, diabetes treatment or other effects in humans.

Interlink Peptides supplies Retatrutide exclusively as a laboratory research material.

Handling & Storage

Store Retatrutide in its lyophilised form at approximately −20 °C, protected from light and moisture.

Once reconstituted with water, store refrigerated at approximately 2–8 °C.

Allow the sealed vial to reach an appropriate laboratory working temperature before opening to minimise condensation inside the vial.

Avoid unnecessary repeated freeze-thaw cycles. Preparation, solvent selection and experimental handling should be determined according to the receiving laboratory’s own validated procedures.

Quality & Testing

Certificate of Analysis documentation is available for Retatrutide.

The COA provides analytical information relating to the tested material. Exact identity, purity and other specifications should be confirmed against the Certificate of Analysis applicable to the relevant batch.

This documentation provides researchers with additional analytical information when evaluating material for laboratory research applications.

Explore our full range of research peptides for laboratory and scientific research applications.

Lower-quantity Retatrutide 10mg, Retatrutide 20mg and Retatrutide 30mg presentations are also available for research requiring different quantities of material.

Frequently Asked Questions

What is Retatrutide?

Retatrutide is a synthetic peptide investigated for activity involving the GIP, GLP-1 and glucagon receptors.

Why is Retatrutide described as a triple agonist?

The description refers to its investigated activity involving three receptor systems: GIP, GLP-1 and glucagon.

What is the difference between the Retatrutide strengths?

Our 10mg, 20mg, 30mg and 40mg presentations contain the same research compound. The difference is the quantity of Retatrutide supplied per vial.

How does Retatrutide differ from Tirzepatide?

Tirzepatide is investigated for dual GIP and GLP-1 receptor activity, while Retatrutide additionally incorporates glucagon-receptor activity.

Is a Certificate of Analysis available?

Yes. Certificate of Analysis documentation is available for Retatrutide. Researchers should refer to the COA applicable to the relevant batch for exact analytical specifications.

How should Retatrutide be stored?

Store the lyophilised product at −20 °C, protected from light and moisture. Once reconstituted with water, store refrigerated at 2–8 °C.

Research Use Only

Interlink Peptides supplies Retatrutide 40mg strictly for in-vitro laboratory and scientific research purposes.

This product is not intended for human or animal consumption, medical treatment, therapeutic use or clinical application.

We do not provide dosing or administration guidance. Purchasers are responsible for ensuring that their intended use complies with applicable laws and institutional requirements.